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Background. Inﬂiximab (INF) has been shown to be beneﬁcial in treating refractory uveitis, however, no data exist on optimal
dosing and the eﬃcacy of higher dosing. Objectives.T oc o m p a r et h ee ﬃcacy of low-dose (LD) (<10mg/kg), moderate-dose
(MD) (≥10–15mg/kg), and high-dose (HD) INF (≥15–20mg/kg) in the treatment of uveitis. Methods. Retrospective chart review
children with uveitis diagnosed at Childrens Hospital Los Angeles and Millers Children’s Hospital, CA, USA. Results.O ft h e3 4
INF-treated children, 6 patients received LD, 19 received MD, and 9 received HD. Average disease duration prior to therapy was
10.6, 24.6, and 37.1 months each group, respectively. Topical steroids were discontinued after an average of 3 months, 9.5 months,
and 10.2 months in the LD, MD, and HD groups, respectively. We found that 66% of patients receiving LD, 42% of MD, and 66%
receiving HD INF failed therapy and required either dose escalation or alternate medication for disease control. Conclusions.I N F
is beneﬁcial in the treatment of uveitis, and dose escalation up to 4 times above the approved dose is often necessary to achieve
disease control in patients with uveitis. Doses < 10mg/kg every 4 weeks may not be suﬃcient to control disease.
1.Introduction
The term uveitis deﬁnes several ocular disease states char-
acterized by inﬂammation of the entire or individual parts
of the uveal tract including iris, ciliary body, or choroid.
Uveitis can be classiﬁed by location in the eye as anterior
uveitis or iridocyclitis, intermediate uveitis or pars planitis,
and posterior uveitis or by primary and secondary uveitis,
whereby primary uveitis refers to intraocular inﬂamma-
tion of unknown etiology, and secondary uveitis refers to
inﬂammatory ocular conditions that are either associated
with systemic, intrinsic, or infectious diseases. Uveitis is the
most common ocular manifestation of childhood rheumatic
diseases such as juvenile idiopathic arthritis (JIA) and is the
third most common preventable cause of blindness in the
developed world [1, 2]. The risk of blindness is higher in
children compared to the adult population mostly because
of the higher rate of posterior uveitis [3].
The etiology and pathogenesis of uveitis is not well
established, and multiple theories exist. Animal model data
suggest that autoimmune uveitis is driven by a predominant
Th e l p e r - 1( T h - 1 )r e s p o n s eo fa u t o r e a c t i v eTc e l l s[ 4, 5].
Th1 cells produce the cytokines such as interleukin- (IL-) 2,
IL-12, and IL-18 [6], while cell-mediated immunity is
mainly associated with tumor necrosis factor (TNF)-α [7, 8].
Intravitreal injection of TNF-α in rabbits [9] and in rats
[10] induces acute uveitis characterized by an increase in
ﬂare (aqueous humor protein) and a polymorphonuclear
inﬁltrate in the anterior chamber, suggesting that TNF-α
may be an initiating factor in the pathogenesis of uveitis.
ElevatedlevelsofIL-1β andTNF-αinthevitreousandserum
of patients with uveitis suggests that uveitis is driven by a
systemic inﬂammatory response [11]. It has been postulated
that both TNF-α and IL-1β in conjunction with vascular
endothelial growth factor (VEGF) lead to increased vascular
permeability and damage in the blood retinal barrier (BRB)
[12, 13]. The damage in the BRB leads to increase in
transendothelial transport activity and exposure of the inner
eye to the immune attack [14] .I L - 6a n dI L - 1m a ya c ta sl o c a l
ampliﬁcation signals in chronic eye inﬂammation after the
BRB has been breached. Other proinﬂammatory cytokines
such as IL-2, IL4, IL-8, IL-12, IL-15, and IL17 along with2 ISRN Rheumatology
chemokines such as metalloproteinases play an important
role in the maintenance of chronic inﬂammation of the eye
[15–17]. It has been shown that diﬀerent cytokines dominate
in diﬀerent types of autoimmune uveitis. IL-1 and TNF-α
are predominant cytokines in anterior uveitis [18], while IL-
6, IL-12, and IL-23 are predominant in the Vogt-Koyanagi-
Harada (VKH) syndrome [19, 20]. IL-6 and IL-12 are the
predominant cytokines in Behcet’s syndrome [21].
A variety of immunomodulatory agents are used in the
management of uveitis. These include among others methot-
rexate, cyclosporine, and mycophenolate mofetil [22–24].
Anti-TNF agents like etanercept (ETN), adalimumab, and
INF have been successfully used in the management of
treatment refractory uveitis and several retrospective case
series describe the use of INF in pediatric uveitis [25, 26].
Comparisons between INF and ETN in the treatment of
uveitis have also been well described in the literature [27].
Saurenmann et al. retrospectively studied 21 children treated
with ETN [11]a n dI N F[ 13]. They concluded that patients
receiving INF had a better response as compared with those
receiving ETN (P = 0.048). Tynj¨ al¨ a et al. retrospectively
reviewed children on either INF or ETN and concluded that
patients receiving INF had more improvement in uveitis
activity and a reduced number of ﬂares per year (P =
0.015) compared to ETN. An international cross-sectional
survey of pediatric rheumatologists was done by Foeldvari
and Wierk. and showed that INF was found to be more
eﬃcacious; 70% of INF patients showed a good response
compared to 53% of patients on ETN. Vazquez-Cobian et al.
conducted a prospective study of adalimumab in pediatric
uveitis (n = 14) and showed decreased inﬂammation in
13/14 patients and with a sustained response for 18 months
after initiation of therapy [28]. A retrospective study by
Biester et al. evaluated adalimumab in refractory uveitis (n =
18) and showed that sixteen patients had a good response, 15
o fw h i c hw e r ea b l et os t o ps t e r o i dt h e r a p y[ 29].
INF is a chimeric monoclonal antibody that binds to and
inhibits tumor necrosis factor alpha, a cytokine that plays
an important role in a variety of inﬂammatory processes,
includinginductionofproinﬂammatorycytokines,enhance-
ment of leukocyte migration, activation of neutrophil and
eosinophil activity, induction of acute phase reactants and
other liver proteins, and tissue degrading enzymes produced
by synoviocytes and chondrocytes [30–32]. Initial studies
with INF in uveitis secondary to Behcet’s disease used
traditional arthritis doses of INF [33]. Studies done in rabbit
eyes show that high dose (20mg/kg) of INF successfully
preventing endotoxin-induced uveitis [34]. Kahn et al. did a
retrospectivestudyon17patientswithchronicnoninfectious
uveitis who were treated with INF in high doses 10–20mg/kg
with a favorable outcome [30, 33]. However, no data exist on
optimal dosing regimens in children, and the true eﬃcacy of
higher dosing remains unclear.
The objective of our study was to compare the eﬃcacy
of low-dose (LD) at <10mg/kg IV, moderate-dose (MD)
at ≥10mg/kg to 15mg/kg IV, and high-dose INF (HD)
at ≥15mg/kg–20mg/kg IV given monthly in the treatment
of various forms of uveitis.
2. Patients andMethods
This study was conducted at the Pediatric Rheumatology
Core at Children’s Hospital Los Angeles (CHLA) and Miller
Children’s Hospital Long Beach (MCH) from November,
2008 to December, 2009. The study population included
children ≤21 years of age with uveitis who received INF
therapy. We identiﬁed 34 children with various forms of
uveitis of whom received INF for greater than one year and
were included in the study.
We performed a comprehensive medical record review
using a standardized instrument to identify demographic
information and clinical characteristics of the disease. We
also collected age, gender, ocular and systemic diagnosis,
previous and current medications, duration of each medica-
tion, and markers of inﬂammation and ocular inﬂammatory
parameters. We documented dosage of INF administered
and assigned patients to three groups depending on the INF
dosagetheyreceived.PatientswhoreceivedINFat<10mg/kg
given IV every four weeks were categorized as low dose (LD).
Those who received INF given ≥10 to <15mg/kg IV every
four weeks were categorized under moderate dose (MD),
and those who received INF given every four weeks at ≥15
to 20mg/kg IV were categorized into the high-dose (HD)
group. Ophthalmological and laboratory parameters were
recorded on these patients for one year after starting the INF
therapy.
We deﬁned uveitis and recorded disease activity using
the standardization of uveitis nomenclature (SUN) grading
scheme and terminology [35]. Accordingly, inactive disease
is grade 0 cells, worsening activity is deﬁned as two-step
increases in the level of inﬂammation, improved activity
is a two-step decrease in the level of inﬂammation, and
remission is deﬁned as inactive disease for ≥3 months after
discontinuingalltreatmentsforeyedisease.Thestandardiza-
tion of uveitis nomenclature (SUN) working group grading
scheme [35] for anterior chamber cells and ﬂare was also
used to monitor the clinical improvement. In this system,
the grading of the anterior chamber cells varies from 0 to
4+. This reﬂects cells in a ﬁeld which is the size of 1mm
by 1mm slit beam. According to the SUN working group
grading for the cell count, grade 0 is <1 cells/ﬁeld, grade 0.5
is1–5cell/ﬁeld,grade1+is6–15cells/ﬁeld,grade2+is16–25
cells/ﬁeld, grade 3+ is 26–50 cells/ﬁeld, and grade 4+ is >50
cells/ﬁeld. Flaring is graded as follows: grade 0 corresponds
to no ﬂare, grade 1+ is faint, grade 2+ is moderate ﬂare with
clear iris and lens details, grade 3+ is marked ﬂare with hazy
irisandlensdetails,andgrade4isintenseﬂarewithﬁbrinous
aqueous [35].
All patients who received INF were pre-medicated
with acetaminophen (10–15mg/kg) and diphenhydramine
(0.5mg/kg). Infusions were given initially every two weeks
for the ﬁrst two weeks and then every 4 weeks. All patients
were monitored with routine laboratory analysis including
complete blood count, comprehensive metabolic panel,
erythrocyte sedimentation rate, C-reactive protein, and
human antichimeric antibodies (HACA). Ophthalmological
evaluations were done by several experienced pediatric
ophthalmologists or pediatric uveitis specialists. EvaluationsISRN Rheumatology 3
were performed every two to four weeks depending upon
the severity of the disease activity. Ocular outcome was
assessed by cell count in the anterior chamber (ACD), ﬂare,
intraocular pressure (IOP), improvement in visual acuity
(VA), and ability to reduce or stop concomitant topical or
systemic steroids.
3.StatisticalAnalysis
We performed descriptive analyses of the above. Testing of
proportions was performed using Chi-squared or Fisher’s
exacttestasappropriate.P valueswereconsideredsigniﬁcant
if they were ≤0.05. When Spearman rank correlation was
done with respect to dose and outcome, the Spearman rho
was 0.123 with a P value of 0.67. We used STATA version 10
software to perform all calculations.
4. Results
Of the 34 children enrolled in the study, all patients had
bilateral eye disease. Sixteen (47%) had anterior uveitis, 11
(32%) patients had panuveitis, ﬁve (15%) had posterior
uveitis, and two (6%) had intermediate uveitis. The mean
age at diagnosis of uveitis was 8.5 years (range 1–15 years).
Of the 34 patients, 16 (47%) had idiopathic uveitis, 6 (18%)
had uveitis associated with oligoarticular juvenile idiopathic
arthritis (JIA), 3 (9%) had uveitis secondary to polyarticular
JIA, 3 (9%) had uveitis associated with enthesitis-related
arthritis, 2 (6%) had Vogt-Koyanagi-Harada disease (VKH),
and one patient each had uveitis associated with chronic
noninfectious osteomyelitis (CNO), sarcoidosis, Blau’s syn-
drome, and psoriatic arthritis. Table 1 demonstrates the
characteristics of our study population.
The mean age of the patients at the start of the INF
was 11.23 years (range 2–20 years). At the initiation of INF,
62% (21/34) of patients were ≥10 years of age. The mean
duration of uveitis prior to INF treatment was 2.62 years
(2–8 years). The mean duration of steroid treatment prior
to start of disease modifying antirheumatic drugs (DMARD)
therapy was 2 years (0.6–4.6 years). Prior to INF therapy, all
patients had been treated with steroids. This included 15/34
(44%)patientsthatreceivedtopicalsteroidsand19/34(56%)
patients that were on both topical and systemic steroids.
The average dose of systemic steroid was 0.25mg/kg, and
the maximum dose was 20mg per day for a mean period
of 2.8 months. Topical prednisone administration varied
signiﬁcantly from every hour while awake to once a day.
Based on the dosage given, there were 6 (18%) patients
assigned to the LD group, 19 (56%) patients to the MD
group, and 9 (26%) patients to the HD group. Dosing was
determined by the primary pediatric rheumatologist on the
basis of disease duration, disease activity at the time of
presentation, and prior medication failures.
Overall, after six months of INF therapy, 25 (74%)
patients had improvement in anterior chamber cell density,
27 (80%) had improvement in ﬂare, and 20 (58.8%) had
improved in visual acuity. We also found that 27 (80%) were
able to wean topical steroids and 20 (58.8%) were able to
discontinue topical steroids. However, there still remained
7/34 (21%) patients that were unable to wean the topical
prednisone at six months of followup. Human antichimeric
antibodies (HACA) were negative in 14/34 (41%) tested
patients. These included 6 patients (67%) from the HD, 4
(21%) from the MD, and 4 (67%) from the LD groups.
After one year of INF therapy, the anterior chamber
cell density showed improvement in 67%, 68%, and 78%
of patients in the LD, MD and HD groups, respectively.
Improvement in ﬂare was noted in 100%, 84% and 67% of
the LD, MD, and HD, respectively. VA improved in 17%,
32%, and 56% in the LD, MD, and HD, respectively. The
improvement in IOP was 11% in the MD, and 44% in the
HD group. Topical or oral prednisone was weaned in 83% of
patients in the LD, 74% in the MD, and 89% of the patients
in the HD group. Table 2 compares the ocular ﬁndings of
patients at baseline and at 1 year of followup.
4.1. Low-Dose Group. Out of the 6 children in the LD group,
one patient was started at 3mg/kg and was advanced to
5mg/kg after the ﬁrst 3 months and continued on this dose
for the remaining 9 months. Four of the 6 (67%) patients
were started on 5mg/kg but required escalation of dosage
to 10mg/kg due to lack of eﬃcacy after 3.5 months. Only
one patient who was started at 5mg/kg that continued on
the same dose during the entire observational period.
Twopatientswereabletoweantopicalprednisonewithin
atwo-monthperiodandwereabletostopat3months.There
was also improvement in ocular parameters noted in these 2
patients. The anterior cell chamber density (ACD) was 1.5
OU, while at 12 months, the ACD decreased to zero OU.
Similarly, ﬂare was 1.6 and 1.3 in left eye (OS) and right
eye (OD) initially, and at the end of study period, the ﬂare
was zero OU. The remaining 4/6 patients were advanced to
the MD group and subsequently were able to stoptopical
prednisone after nine months.
4.2. Moderate-Dose Group. Of the 19 patients in the MD
group, 6 (31%) had anterior uveitis, while 13 (69%) had
panuveitis, posterior uveitis, or intermediate uveitis. Eleven
(58%) patients in the MD group improved signiﬁcantly
duringthestudyperiod.Theaveragetimetodiscontinuation
of steroids was 9.5 months (6–19 months) in this group.
Among the 11 patients who were weaned oﬀ steroids and
remainedonMDofINF,ACDimprovedin9(81%)patients,
and ﬂare improved in 7 (64%) patients. Other markers like
I O Pi m p r o v e di n2( 1 8 % )c h i l d r e n ,a n dV Ai m p r o v e di n
5 (45%) children. The mean ACD in OS and OD was 1.7
and 1.6 and decreased to 0.4 and 0.3 in OS and OD by one
year. The mean ﬂare was 1.8 and 1.6 in OS and OD at the
start of therapy and improved to 0.05 and 0.15 OS and OD,
respectively, by 12 in months.
Eight (42%) children required a dose escalation after an
averageperiodof7.5month(range6.5–9months)secondary
to worsening of the disease and required dosage escalation to
HD group. All of the patients that were advanced to HD had
nonanterior uveitis.
4.3. High-Dose Group. This group was distinct for the fact
that patients had a higher percentage of nonanterior disease,4 ISRN Rheumatology
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a higher degree of chronicity, disease severity, and a higher
rate of prior DMARD failures, which explains the use of
initial higher dosing. Of the 9 patients in the HD group,
44% had anterior uveitis, and 55% had panuveitis, posterior
uveitis, or intermediate uveitis.
The mean ACD at the initiation of therapy in this group
was 2.1 and 1.7 in OS and OD, respectively, and decreased
signiﬁcantly to 0.8 and 0.5 in OS and OD, respectively, by
oneyear.Similarly,ﬂareattheinitiationofthetreatmentalso
decreased from 2.1 and 1.8 in OS and OD to 0.5 and 0.2 in
OS and OD, respectively. Despite the use of high-dose INF,
7 (78%) patients were unable to wean topical prednisone
at six months of INF therapy. Six other patients (67%)
were changed to another class of medications including
abatacept, rituximab, or daclizumab due to worsening of
disease activity. One of these patients had been started on
15mg/kg that required dose escalation to 20mg/kg at 5.4
months due to inadequate response.
5. Discussion
Our study conﬁrmed that treatment with INF is beneﬁcial
in the treatment of uveitis and dose escalation up to 4 times
above the approved dose is often necessary to achieve disease
control. Overall, 80% of patients had a good response to the
INFtreatmenteventhoughover35%ofthepatientsrequired
adoseescalationto ≥10mg/kg(4fromLDtoMDand8from
MD to HD) and 32/34 (94%) patients in this population
received ≥10mg/kg of INF at the end of the observation
period.Treatmentfailuretothechosendoseoccurredin6/34
(18%) of patients, all of whom were in the HD group.
The justiﬁcation of using very high doses at the initiation
of therapy in our cohort was based on the characteristics
of the patients encountered. Assuming that inﬂammatory
eye disease follows the same rules as any other autoimmune
disease, the longer patients are not receiving appropriate
treatment, the more diﬃcult to achieve a meaningful
response late into the disease. In our study, the mean
duration of uveitis prior to starting treatment was longer in
the HD (37 months) and MD (25 months) group compared
with LD (11 months) group. This may indicate that patients
withprolongeddurationofillnessarelesslikelytorespondto
lower doses and longer dose intervals. As an additional poor
prognostic factor, there were 11 patients with panuveitis, ﬁve
with posterior uveitis, and two with intermediate uveitis in
this group. These are traditionally more diﬃcult diseases to
control. As a result, visual acuity was also worse in the HD
group at the initiation of the treatment compared to the LD
group. Legal blindness (≥20/200) was present in 22 eyes.
Similarly band keratopathy (BK) and keratic precipitates
(KP) were seen in 15/56 (27%) eyes, and glaucoma was
observed in 28/56 (50%) eyes.
In the 10 patients who had anterior uveitis in the MD
and HD group, the higher dose approach was chosen due
to a very high level of acuity and severity in the initial
ophthalmology exam. Although they responded very well to
high dose of INF, their disease duration prior to initiation
of INF was shorter than that in the other patients. This
may suggest that an early and aggressive treatment approach
may lead to better outcomes. Comparatively, the initial LD
approach was utilized on those patients that had mostly
anterior uveitis and less disease severity when compared
with the HD or MD group. Two patients in the LD group
achieved medicated remission by the third month. However,
persistence of disease prompted four patients (67%) in the
LD group to escalate dosing to the MD group at an average
time of 3.5 months. The patients who were advanced to MD
groupsubsequentlydidwellandwereabletostopprednisone
after an average period of nine months. Eight (42%) patients
in the MD group were advanced to the HD group due to
the persistence of active disease and did well for the entire
observational period. Six patients (67%) from the HD group
were changed to other medications due to poor response
in the ﬁrst six months of treatment. The failure rate to the
chosen INF dose in LD and HD was similar at 67%, while
the MD had a lesser failure rate (42%). The negative HACA
result in all the tested patients suggests that these antibodies
had no inﬂuence on the lack of response to INF.
We acknowledge our study has limitations. The lim-
itations of this study are those inherent to retrospective
studies. Our study has some potential confounding variables
including the tailoring of therapy to each patient, underlying
diﬀerences in cause of uveitis, severity of disease, duration
of the disease, and concomitant immunomodulatory treat-
ment. It was conducted in a single geographic area and,
therefore, may not be generalizable to other populations.
However, this is a pilot study, and although small in number
of participants, it is the ﬁrst to address the impact of dosage
in the treatment of uveitis in the pediatric population. We
also acknowledge that the improvement in IOP noted in MD
a n dH Dg r o u p sm a yn o tb ea ne ﬀect of INF alone and the
concomitant weaning of steroids may have played a role.
The data from our cohort do not suggest optimal dosing,
as patients in all three groups had signiﬁcant failure rates,
and the groups were not ideally comparable as disease
duration,severity,anduveitistypesdiﬀeredineachgroup.In
this study cohort, risk factors for a poor prognosis included
panuveitis, posterior uveitis, disease chronicity, prolonged
topical and systemic steroid use, and prior DMARD failures.
Nevertheless, despite using higher doses no serious side
eﬀects were noted during the observation period, suggesting
that INF even at higher doses might be safe in the short term.
Our study emphasizes the necessity of well-controlled trials
to address the issue of standardization of dosing the optimal
timing and duration of INF therapy in pediatric uveitis.
Abbreviations
INF: Inﬂiximab
ETN: Etanercept
SUN: Standardization of uveitis nomenclature
JIA: Juvenile idiopathic arthritis
TNF: Tumor necrosis factor
LD: Low dose
MD: Moderate dose
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